Sally Felton

Statistics

Publications

Citations

272

H-Index

Active since

2000

Affiliations

The University of Texas at San Antonio Health Science Center(Current)

Sally Felton is an author at The University of Texas at San Antonio Health Science Center specializing in dose-limiting toxicity assessment, chemotherapy dose-limiting toxicity, and pharmacology.

Publications per year

2000–2002

Publications

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Amita Patnaik, Eric K. Rowinsky, Miguel A. Villalona et al. · PubMed · 2002 · 124 citations

Medicine, Oncology, Pharmacology +11

Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies

Sabine Eckhardt, Sharyn D. Baker, Carolyn D. Britten et al. · Journal of Clinical Oncology · 2000 · 56 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel

Manuel Hidalgo, Cheryl Aylesworth, Lisa A. Hammond et al. · Journal of Clinical Oncology · 2001 · 42 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory Properties

Anthony W. Tolcher, S. Gail Eckhardt, John G. Kuhn et al. · Journal of Clinical Oncology · 2001 · 36 citations

Medicine, Oncology, Pharmacology +16

Phase I and Pharmacokinetic Study of the Differentiating Agent Vesnarinone in Combination With Gemcitabine in Patients With Advanced Cancer

Amita Patnaik, Eric K. Rowinsky, Brinda Tammara et al. · Journal of Clinical Oncology · 2000 · 14 citations

Medicine, Oncology, Pharmacology +14

1–5 of 5